0000000000905292

AUTHOR

Succurro E

showing 2 related works from this author

Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study.

2014

none 330 Women live longer and outnumber men. On the other hand, older women develop more chronic diseases and conditions such as arthritis, osteoporosis and depression, leading to a greater number of years of living with disabilities. The aim of this study was to describe whether or not there are gender differences in the demographic profile, disease distribution and outcome in a population of hospitalized elderly people.Retrospective observational study including all patients recruited for the REPOSI study in the year 2010. Analyses are referred to the whole group and gender categorization was applied.A total of 1380 hospitalized elderly subjects, 50.5\% women and 49.5\% men, were conside…

GerontologyMaleActivities of daily livingSettore MED/09 - Medicina InternaGeriatric MedicineComorbidityDisease distribution; Elderly; Sex-gender difference; In-hospital mortalityDisease distribution; Elderly; In-hospital mortalityElderlyRetrospective StudieDisease distributionActivities of Daily Livinggender80 and overDepression (differential diagnoses)Aged 80 and overeducation.field_of_studyhospitalized elderlyDepressionMortality rateMedicine (all)gender hospitalization elderlyHospitalizationIn-hospital mortalityItalyoutcomeGeriatric Depression ScaleFemaleInpatientHumanPopulationGender-differencesex-gender differencesFollow-Up StudieCognition DisorderDisease distributionmedicineInternal MedicineDisease distribution; Elderly; In-hospital mortality; Sex-gender difference; Aged; Aged; 80 and over; Chronic Disease; Cognition Disorders; Comorbidity; Depression; Female; Follow-Up Studies; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Morbidity; Retrospective Studies; Sex Distribution; Activities of Daily Living; Inpatients; Internal MedicineHumansDisease distribution; Elderly; In-hospital mortality; Sex-gender difference; Aged; Aged 80 and over; Chronic Disease; Cognition Disorders; Comorbidity; Depression; Female; Follow-Up Studies; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Morbidity; Retrospective Studies; Sex Distribution; Activities of Daily Living; Inpatients; Internal MedicineSex DistributioneducationGeriatric AssessmentSex-gender differenceAgedRetrospective StudiesInpatientsbusiness.industrySettore MED/09 - MEDICINA INTERNARetrospective cohort studymedicine.diseaseComorbidityGender-differences; disease distribution; outcome; hospitalized elderlyIn-hospital mortalityElderlyMood disordersChronic DiseaseDisease distribution; Elderly; In-hospital mortality; Sex-gender difference; Aged; Aged 80 and over; Chronic Disease; Cognition Disorders; Comorbidity; Depression; Female; Follow-Up Studies; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Morbidity; Retrospective Studies; Sex Distribution; Activities of Daily Living; Inpatientsdisease distribution; elderly; in-hospital mortality; sex-gender differencesMorbiditybusinessDisease distribution; Elderly; In-hospital mortality; Sex-gender difference; Aged; Aged 80 and over; Chronic Disease; Cognition Disorders; Comorbidity; Depression; Female; Follow-Up Studies; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Morbidity; Retrospective Studies; Sex Distribution; Activities of Daily Living; Inpatients; Internal Medicine; Medicine (all)Cognition DisordersFollow-Up Studies
researchProduct

Liraglutide and Renal Outcomes in Type 2 Diabetes.

2017

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a co…

MaleSettore MED/09 - Medicina InternaAcute Kidney Injury; Aged; Albuminuria; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kidney Failure Chronic; Liraglutide; Male; Middle AgedType 2 diabetes030204 cardiovascular system & hematologyurologic and male genital diseasesGLOMERULAR-FILTRATION-RATEKIDNEY-FUNCTIONDISEASElaw.inventionKidney Failurechemistry.chemical_compound0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawMedicineDiabetic NephropathiesHypoglycemic Agents.Settore MED/49 - Scienze Tecniche Dietetiche ApplicateChronicRISKKidneyAcute kidney injury11 Medical And Health SciencesGeneral MedicineAcute Kidney InjuryMiddle AgedIntention to Treat Analysismedicine.anatomical_structureCreatinineTRIALFemaleliraglutide randomized controlled trial type 2 diabetes renal outcomesLife Sciences & BiomedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyRenal function030209 endocrinology & metabolismCARDIOVASCULAR OUTCOMESFollow-Up Studie03 medical and health sciencesMedicine General & InternalDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicineDiabetes MellitusAlbuminuriaHumansHypoglycemic AgentsIntensive care medicineAgedCreatinineScience & Technologybusiness.industryLiraglutideMORTALITYLiraglutidemedicine.diseaseINTENSIVE GLUCOSE CONTROLINDIVIDUALSDiabetes Mellitus Type 2chemistryDiabetic NephropathieKidney Failure ChronicLEADER Steering Committee and InvestigatorsbusinessFollow-Up Studies
researchProduct